Scalper1 News
Gilead Sciences (GILD) shares are backsliding Wednesday on news that the patient drop-out rate for hepatitis C drug Sovaldi is quadruple that of clinical trials. In addition, the biotech’s Phase 2 study results that show its pancreatic cancer treatment failed to show any clinical benefits to patients. Shares of Gilead fell 1.8% to 102.84 in afternoon trading on the stock market today. The stock hit a record 110.84 on Sept. 3. CVS Health Research Scalper1 News
Scalper1 News